Prestige News

Total 72
Number Thumbnail Title Author Date Votes Views
72 Prestige Biopharma IDC CEO Ko Sang-seok Purchases Company Shares on the Open Market
김** | 08:58 | Votes 0 | Views 45
김** 08:58 0 45
71 Prestige Biopharma’s Tuznue Secures Brazilian GMP Certification, Supporting Latin American Approval Process
김** | 2026.08.25 | Votes 0 | Views 798
김** 2026.08.25 0 798
70 Prestige Biopharma Files Patent Application for TASA™, a Blood-Based Pancreatic Cancer Diagnostic Platform
김** | 2026.08.12 | Votes 0 | Views 1077
김** 2026.08.12 0 1077
69 Prestige Biopharma Positions PBP1710 as Its Next-Generation Growth Driver
김** | 2026.08.11 | Votes 0 | Views 1394
김** 2026.08.11 0 1394
68 Prestige Biopharma CEO Soyeon Park Purchases Approximately 70,000 Additional Shares, Bringing Total Purchases to 161,765 Shares
김** | 2026.08.04 | Votes 0 | Views 1478
김** 2026.08.04 0 1478
67 Prestige Biopharma IDC Publishes Preclinical Efficacy Results of IDC007 in International Academic Journal
김** | 2026.07.16 | Votes 0 | Views 2572
김** 2026.07.16 0 2572
66 Prestige Biopharma Unveils Follow-up Clinical Development Strategy for Pancreatic Cancer Drug Candidate PBP1510 at ESMO GI
김** | 2026.07.09 | Votes 0 | Views 3247
김** 2026.07.09 0 3247
65 Prestige Biopharma IDC Publishes Preclinical Results for Bispecific Antibody IDC007, Targeting Immunotherapy Side Effects
김** | 2026.07.07 | Votes 0 | Views 3088
김** 2026.07.07 0 3088
64 Prestige Biopharma Enters Strategic MOU with Charles River , a Global Contract Research Organization
김** | 2026.07.02 | Votes 0 | Views 3967
김** 2026.07.02 0 3967
63 Prestige Biopharma to Present Clinical Development Strategy for Pancreatic Cancer Candidate at ESMO GI 2026
김** | 2026.06.30 | Votes 0 | Views 4267
김** 2026.06.30 0 4267